PD-L1 Lung (Atezolizumab), IHC

94480

Formalin-fixed, paraffin-embedded tissue block, NSCLC, collected in an IHC specimen transport kit

Minimum 5 unstained positively charged slides submitted in an IHC specimen transport kit

FFPE: State any other type of fixative used. A pathology report which includes the paraffin block number, and both macroscopic and microscopic evaluation and diagnosis, should be sent with the specimen.

Room temperature

Tissue block
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable

Slides
Room temperature: 30 days
Refrigerated: 30 days
Unacceptable

Baked or melted slides • Previously stained slides • Cytospins • Tissue types other than lung cancer specimens • Cytology cell block • Decalcified specimens • Fixatives other than formalin

Set up: Mon-Fri; Report available: 4-6 days

See Laboratory Report

TECENTRIQ is the first FDA-approved anti-PD-L1 cancer immunotherapy which is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum- containing chemotherapy. Determining a patient's PD-L1 expression level can provide insight into the survival benefit that may be achieved from treatment with TECENTRIQ. PD-L1 expression in ≥50% tumor cells (TC) or ≥10% tumor-infiltrating immune cells (IC) (lymphocytes, macrophages, dendritic cells, and granulocytes) determined by VENTANA PD-L1 (SP-142) Assay/Quest PD-L1 Lung (Atezolizumab) in non-small cell lung cancer tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).